Objective — to assess the results of combined treatment in patients with high-grade cervical intraepithelial lesions (HSIL) associated with human papillomavirus and use of the mucosal immunity inducer superlymph in the pre- and postexcision periods via clinical, cytological and colposcopic monitoring. Subject and methods. Sixty women aged 20 to 50 years with HSIL were examined. A study group (n=30) received combined treatment using the local immunity inductor superlymph and radiowave excision; a control group (n=30) had only local radiowave excision of the lesion zone after sanitation preoperative preparation. All the patients underwent comprehensive examination, including general and gynecological examination, extended colposcopy, evaluation of local and systemic immunity by enzyme immunoassay, vaginal smear bacterioscopy, and quantitative determination of the composition of the vaginal microflora by polymerase chain reaction. Results. As a result, at 6 months after the treatment, there was complete (100%) elimination of high-risk human papillomavirus in the study group versus 63% virus elimination in the control group, the absence of cellular atypia in the cytological smears in the study group versus 17% in the control group, as well as positive changes in the colposcopic pattern in 83% of the patients in the study group versus 60% in the control group. The use of superlymph led to a reduction in the iodine-negative areas by an average of 3.5—4 times. At 30 days of treatment, the study group showed complete (100%) epithelialization versus 80% in the control group. Conclusion. The use of superlymph positively affects quality of life in patients after destructive treatment for HSIL, which allows one to recommend the drug for use in the combination therapy for cervical dysplastic lesions.